James Paul Douglass
age ~78
from Stuart, FL
- Also known as:
-
- James P Douglass
- Paul James Douglass
- James P Dogglas
- James P Douglas
- James P Godshalk
- John Douglass
- Phone and address:
- 3954 SE Topsail Ct, Stuart, FL 34997
James Douglass Phones & Addresses
- 3954 SE Topsail Ct, Stuart, FL 34997
- Cape Carteret, NC
- 1703 Ocean Dr, Emerald Isle, NC 28594 • 9196771666
- 6411 Ocean Dr #W, Emerald Isle, NC 28594 • 9196771666
- 104 Willesden Dr, Cary, NC 27513 • 9194271332 • 9196770687
- 206 New Rail Dr, Cary, NC 27513 • 9195396571
- 3320 Walnut Creek Pkwy S #I, Raleigh, NC 27606 • 9195396571
- Port Deposit, MD
- Manhattan, KS
- 104 Willesden Dr, Cary, NC 27513 • 9194271332
Work
-
Position:Medical Professional
Education
-
Degree:Graduate or professional degree
Isbn (Books And Publications)
The Non-Violent Cross: A Theology of Revolution and Peace
view sourceAuthor
James W. Douglass
ISBN #
0225274485
Lightning East to West: Jesus, Gandhi and the Nuclear Age
view sourceAuthor
James W. Douglass
ISBN #
0824505875
Us Patents
-
Composition And Method For Inhibiting Platelet Aggregation
view source -
US Patent:7101860, Sep 5, 2006
-
Filed:Aug 21, 2001
-
Appl. No.:09/934970
-
Inventors:Jose L. Boyer - Chapel Hill NC, US
Gillian M. Olins - Cary NC, US
Benjamin R. Yerxa - Raleigh NC, US
James G. Douglass - Apex NC, US -
Assignee:Inspire Pharmaceuticals, Inc. - Durham NC
University of North Carolina - Chapel Hill NC -
International Classification:A01N 43/04
A61K 31/70 -
US Classification:514 43, 514 42, 514 45, 514 46, 514 47, 514 48, 514 49, 514 50, 514 51, 514 52
-
Abstract:This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of P2Yreceptor antagonist compound, wherein said amount is effective to bind the P2Yreceptors on platelets and inhibit ADP-induced platelet aggregation. The P2Yreceptor antagonist compounds useful for this invention include mononucleoside polyphosphates and dinucleoside polyphosphates of general Formula I, or salts thereof The present invention also provides compositions comprising mononucleoside polyphosphates and dinucleoside polyphosphates according to Formula Ia and Ib.
-
Dinucleoside Polyphosphate Compositions And Their Therapeutic Use As Purinergic Receptor Agonists
view source -
US Patent:20020103158, Aug 1, 2002
-
Filed:Mar 23, 2001
-
Appl. No.:09/817017
-
Inventors:Janet Rideout - Raleigh NC, US
Benjamin Yerxa - Raleigh NC, US
Sammy Shaver - Chapel Hill NC, US
James Douglass - Apex NC, US -
International Classification:A61K031/711
A61K031/675
A61K031/665
C07H019/20
C07H019/04
C07F009/6512 -
US Classification:514/048000, 514/051000, 514/081000, 514/086000, 544/244000, 544/243000, 536/026210
-
Abstract:The present invention relates to certain novel dinucleotide polyphosphates of general Formulae I, II and III, and formulations thereof which are selective agonists of the P2Y purinergic receptors. They are useful in the prevention, management or treatment of diseases and disorders associated with abnormalities of tissue fluid secretion, hydration and clearance, including chronic obstructive pulmonary diseases (chronic bronchitis, PCD, cystic fibrosis, immobility-associated pneumonia), sinusitis, otitis media, nasolacrimal duct obstruction, dry eye disease, glaucoma, retinal degeneration, and edematous retinal disorders, including retinal detachment, vaginal dryness, and gastrointestinal tract disease. Finally, these novel dinucleotides may be useful for diagnostic purposes, such as the facilitation of sputum induction and expectoration for the analysis of respiratory tract secretions.
-
Compsoitions And Methods For Treating Epithelia And Retinal Tissue Diseases
view source -
US Patent:20030008834, Jan 9, 2003
-
Filed:Feb 27, 2002
-
Appl. No.:10/082998
-
Inventors:Benjamin Yerxa - Raleigh NC, US
James Douglass - Apex NC, US
Sammy Shaver - Chapel Hill NC, US
Ward Peterson - Durham NC, US
Edward Brown - Apex NC, US
Christopher Crean - Apex NC, US -
International Classification:A61K048/00
C07J001/00
A61K038/16
C07H021/04 -
US Classification:514/026000, 514/008000, 514/044000, 530/322000, 536/023100, 536/005000
-
Abstract:The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides.
-
Dinucleoside Polyphosphate Compositions And Their Therapeutic Use
view source -
US Patent:20030207825, Nov 6, 2003
-
Filed:Apr 28, 2003
-
Appl. No.:10/425847
-
Inventors:Janet Rideout - Fuquay-Varina NC, US
Benjamin Yerxa - Raleigh NC, US
Sammy Shaver - Chapel Hill NC, US
James Douglass - Apex NC, US -
International Classification:A61K031/7076
C07H019/04
C07H019/20 -
US Classification:514/043000, 536/026210
-
Abstract:The present invention relates to certain novel dinucleoside polyphosphates of general Formulae I, II and III, and formulations thereof which are selective ligands of the P2Y purinergic receptors. Applicants have discovered that dinucleoside polyphosphates of general Formulae I, II and III are effective in clearing retained mucous secretions, balancing tissue hydration and fluid secretion, and/or inhibiting or preventing early stages of platelet activation, platelet degranulation, and platelet aggregation.
-
Composition And Method For Inhibiting Platelet Aggregation
view source -
US Patent:20040220133, Nov 4, 2004
-
Filed:Mar 31, 2004
-
Appl. No.:10/814007
-
Inventors:Jose Boyer - Chapel Hill NC, US
James Douglass - Apex NC, US
Sammy Shaver - Chapel Hill NC, US
Krzysztof Bednarski - Raleigh NC, US
Benjamin Yerxa - Raleigh NC, US
Gillian Olins - San Diego CA, US -
International Classification:C07H019/04
A61K031/7076
A61K031/7072 -
US Classification:514/047000, 514/050000, 536/026100
-
Abstract:This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutic effective amount of P2Yreceptor antagonist compound, wherein said amount is effective to bind the P2Yreceptors on platelets and inhibit ADP-induced platelet aggregation. The P2Yreceptor antagonist compounds useful for this invention include mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates of general Formula I, or salts thereof. The present invention also provides novel compounds of mononucleoside 5′-monophosphates, mononucleoside polyphosphates, and dinucleoside polyphosphates. The present invention further provides pharmaceutical formulations comprising mononucleoside 5′-monophosphates, mononucleoside polyphosphates, or dinucleoside polyphosphates.
-
Compositions For The Treatment Of Glaucoma Or Ocular Hypertension
view source -
US Patent:20050130931, Jun 16, 2005
-
Filed:Feb 1, 2005
-
Appl. No.:11/049201
-
Inventors:Jose Boyer - Chapel Hill NC, US
Benjamin Yerxa - Raleigh NC, US
Robert Plourde - Chapel Hill NC, US
Edward Brown - Cary NC, US
James Douglass - Apex NC, US -
International Classification:C07H019/04
A61K031/7072
A61K031/675 -
US Classification:514050000, 514086000, 544243000, 536026100
-
Abstract:The present invention is directed to a method of reducing intraocular pressure. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a nucleoside 5′-pyrophosphate pyranoside or analogue, which is defined by general Formula I. The method of the present invention is useful in the treatment or prevention of ocular hypertension, such as found in glaucoma, including primary and secondary glaucoma. The method can be used alone to reduce intraocular pressure. The method can also be used in conjunction with another therapeutic agent or adjunctive therapy commonly used to treat glaucoma to enhance the therapeutic effect of reducing the intraocular pressure. The present invention also provides a novel composition comprising a nucleoside 5′-pyrophosphate pyranoside or analogue.
-
Drug-Eluting Stents Coated With Non-Nucleotide P2Y12 Receptor Antagonist Compound
view source -
US Patent:20060121086, Jun 8, 2006
-
Filed:Nov 4, 2005
-
Appl. No.:11/267941
-
Inventors:Jose Boyer - Chapel Hill NC, US
James Douglass - Apex NC, US
Sammy Shaver - Chapel Hill NC, US -
International Classification:A61K 31/519
A61K 31/52
A61F 2/00 -
US Classification:424426000, 514263240, 514261100
-
Abstract:The present invention provides a drug-eluting stent, wherein the stent is coated with one or more non-mucleotide P2Yreceptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Yreceptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Yreceptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
-
Drug-Eluting Stents Coated With P2Y12 Receptor Antagonist Compound
view source -
US Patent:20060122143, Jun 8, 2006
-
Filed:Nov 4, 2005
-
Appl. No.:11/267834
-
Inventors:Jose Boyer - Chapel Hill NC, US
James Douglass - Apex NC, US
Sammy Shaver - Chapel Hill NC, US -
International Classification:A61K 31/7076
A61K 31/7072
C07H 19/04
A61K 31/675 -
US Classification:514045000, 514049000, 514081000, 514087000, 536026100, 544243000, 544244000
-
Abstract:The present invention provides a P2Yreceptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Yreceptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the stent is placed in a narrowed or damaged arterial vessel, a therapeutically effective amount of the P2Yreceptor antagonist compound is eluted continuously from the stent to the local environment of the stent. The P2Yreceptor antagonist compound-eluting stents are useful in preventing thrombosis and restenosis, and are effective in inhibiting the contraction of vascular smooth muscle cells, inhibiting cell proliferation, and reducing inflammation.
Wikipedia References
James W. Douglass
Resumes
James Douglass
view source
James Douglass
view source
James Douglass
view source
James Douglass
view source
James Douglass
view sourceLocation:
United States
Engineer At United States Department Of Defense
view sourcePosition:
Engineer at United States Department of Defense
Location:
US Military Posts in the Pacific
Industry:
Chemicals
Work:
United States Department of Defense
Engineer
Engineer
Amazon
JFK and the Unspeakable: Why He Died and Why It Matters
view sourceTHE ACCLAIMED BOOK, NOW IN PAPERBACK, with a reading group guide and a new afterword by the author. At the height of the Cold War, JFK risked committing the greatest crime in human history: starting a nuclear war. Horrified by the specter of nuclear annihilation, Kennedy gradually turned away from h...
Author
James W. Douglass
Binding
Paperback
Pages
560
Publisher
Touchstone
ISBN #
1439193886
EAN Code
9781439193884
ISBN #
1
The Nonviolent Coming of God:
view sourceAuthor
James W. Douglass
Binding
Paperback
Pages
254
Publisher
Wipf & Stock Pub
ISBN #
1597526118
EAN Code
9781597526111
ISBN #
6
Gandhi and the Unspeakable: His Final Experiment with Truth
view sourceIn 1948, at the dawn of his country s independence, Mohandas Gandhi, father of the Indian independence movement and a beloved prophet of nonviolence, was assassinated by Hindu nationalists. In riveting detail, author James W. Douglass shows as he previously did with the story of JFK how police and s...
Author
James W. Douglass
Binding
Hardcover
Pages
168
Publisher
Orbis Books
ISBN #
1570759634
EAN Code
9781570759635
ISBN #
2
The Non-Violent Cross: A Theology of Revolution and Peace
view source*** Please Read This *** New book other than Remainder mark on bottom edge - No marks - Ships from Ohio - Next day shipping â€" Free tracking - 14-E-19
Author
James W. Douglass
Binding
Paperback
Pages
320
Publisher
Wipf & Stock Pub
ISBN #
1597526088
EAN Code
9781597526081
ISBN #
3
Resistance and Contemplation: The Way of Liberation
view sourceBook by Douglass, James W.
Author
James W. Douglass
Binding
Paperback
Pages
196
Publisher
Wipf & Stock Pub
ISBN #
1597526096
EAN Code
9781597526098
ISBN #
9
Name / Title
Company / Classification
Phones & Addresses
Principal
Cynthia Godshalk DVM
Veterinary Services
Veterinary Services
206 New Rail Dr, Cary, NC 27513
FIRST MEDICAL STAFFING, INC
PROFESSIONAL RATINGS, LLC
FLOOR GALLERY & DESIGN, INC
PREMIER SHAKER YOUTH BASEBALL, INC
FIRST MEDICAL STAFFING LLC
HEALTH CARE, LLC
CONCEPT INNOVATIONS, LLC
Lawyers & Attorneys
James Douglass - Lawyer
view sourceSpecialties:
Trusts & Estates
ISLN:
922527884
Admitted:
2002
University:
California Southern LS; Riverside CA; California St Univ; San Bernardino CA
Law School:
California Southern Law School, law
James Douglass - Lawyer
view sourceISLN:
907776305
Admitted:
1966
University:
University of Wyoming, B.S.
Law School:
University of Wyoming, J.D.
Classmates
James Douglass
view sourceSchools:
Peter Vetal Elementary School Detroit MI 1978-1983, Ludington Middle School Detroit MI 1983-1984, MacArthur Elementary School Southfield MI 1984-1984, Levey Middle School Southfield MI 1984-1987
Community:
Michael Kulpa
James Lee Douglass
view sourceSchools:
Peru High School Peru IN 1977-1981
Community:
Joyce Greggs, Blane Stapleton, Beth Sawyer
James Douglass
view sourceSchools:
Lakeridge Junior High School Orem UT 1996-1997
Community:
Melissa Dennis, Tom Robertson
James Douglass
view sourceSchools:
Hermitage High School Hermitage AR 1978-1982
Community:
Marty Brown, Margarett Thornton, Chanda Frisby
James Douglass
view sourceSchools:
James Peter Sinnott Junior High School Brooklyn NY 1976-1980
Community:
Laurie Maske, Sharon Connelly, Tony Santiago, Sharon Armstead
James Douglass
view sourceSchools:
Faith Christian Academy Aransas Pass TX 1989-1993
Community:
Juliana Roberts
James Douglass
view sourceSchools:
Clifton Career Development School Austin TX 1984-1988
James Douglass
view sourceSchools:
Clyde High School Clyde TX 1978-1982
Community:
Sandra Olehy, Vicki Martin, Van Davison, Charlie Pat
Googleplus
James Douglass
James Douglass
James Douglass
James Douglass
James Douglass
James Douglass
James Douglass
James Douglass
Plaxo
James F Douglass
view sourceWest Chester, PA
James Douglass
view sourceNews
Oliver Stone Looks Back at 'JFK'
view source- I ask people who criticize: Did you ever read a book? Did you ever read Robert Groden's Absolute Proof, Cyril Wecht's Cause of Death, Josiah Thompson's Six Seconds in Dallas or James Douglass's JFK and the Unspeakable? Did you ever look at the evidence or counter-evidence? And they rarely know any o
- Date: Nov 04, 2013
- Category: U.S.
- Source: Google
The new Christian Grey? Maybe it's one of these guys
view source- James Douglass, author of JFK and the Unspeakable: Why He Died and Why It Matters and playwright Ginny Cunningham, who has written a one-act drama based on the book, will appear Nov. 8 for a 4 p.m. lecture and 7:30 p.m. play reading.
- Date: Oct 16, 2013
- Source: Google
Myspace
Youtube
James Lee Douglass
view source
James Douglass Reilly
view source
Douglass James
view source
James Steve Douglass
view source
James E. Douglass
view source
James Douglass
view source
James Douglass
view source
James Douglass
view sourceFlickr
Get Report for James Paul Douglass from Stuart, FL, age ~78